Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism [Seeking Alpha]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Seeking Alpha
Zovegalisib's mutant-selective PI3Ka inhibition offers a differentiated safety and efficacy profile versus broader PI3K inhibitors, targeting a large, underserved patient population. RLAY's $596M cash position funds operations into 2029, supporting ongoing pivotal Phase 3 and expansion studies across oncology and vascular malformations. Key near-term catalysts include topline Phase 3 ReDiscover-2 data in mid-2026 and potential competitive advantage if Celcuity's gedatolisib underperforms. Tom Werner/DigitalVision via Getty Images Thesis: Zovegalisib Builds Momentum As you know, Oppenheimer upgraded Relay Therapeutics Inc. ( RLAY ) to Outperform from Perform this week, and the stock saw a considerable boost. Since the upgrade on the 26th, shares are up This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote t
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors [Yahoo! Finance]Yahoo! Finance
- Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances [Yahoo! Finance]Yahoo! Finance
- Celcuity Inc.: A Die To Be Cast Before July 2026 [Seeking Alpha]Seeking Alpha
- Reassessing Celcuity (CELC) Valuation After A 51.85% Three Month Share Price Gain [Yahoo! Finance]Yahoo! Finance
- Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 1/29/26 - Form 4
- 1/27/26 - Form 144
- 1/16/26 - Form SCHEDULE
- CELC's page on the SEC website